Related Experiment Video
Updated: Jan 29, 2026
Autoradiography as a Simple and Powerful Method for Visualization and Characterization of Pharmacological Targets
Published on: March 12, 2019
Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Chengqian Yin1, Bo Zhu1, Ting Zhang2
1Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Abstract:
Activating mutations in NRAS account for 20%-30% of melanoma, but despite decades of research and in contrast to BRAF, no effective anti-NRAS therapies have been forthcoming. Here, we identify a previously uncharacterized serine/threonine kinase STK19 as a novel NRAS activator. STK19 phosphorylates NRAS to enhance its binding to its downstream effectors and promotes oncogenic NRAS-mediated melanocyte malignant transformation. A recurrent D89N substitution in STK19 whose alterations were identified in 25% of human melanomas represents a gain-of-function mutation that interacts better with NRAS to enhance melanocyte transformation. STK19D89N knockin leads to skin hyperpigmentation and promotes NRASQ61R-driven melanomagenesis in vivo. Finally, we developed ZT-12-037-01 (1a) as a specific STK19-targeted inhibitor and showed that it effectively blocks oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo. Together, our findings provide a new and viable therapeutic strategy for melanomas harboring NRAS mutations.
Insights
Researchers discovered STK19 as a novel NRAS activator in melanoma. Targeting STK19 with ZT-12-037-01 offers a promising therapeutic strategy for NRAS-mutated melanomas.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Activating NRAS mutations drive 20%-30% of melanomas, yet effective therapies remain elusive.
- Unlike BRAF, NRAS oncogenic drivers lack targeted therapeutic strategies.
- Understanding NRAS activation mechanisms is crucial for developing new melanoma treatments.
Purpose of the Study:
- To identify novel activators of NRAS in melanoma.
- To investigate the role of STK19 in NRAS-mediated melanomagenesis.
- To develop and evaluate a STK19-targeted inhibitor for NRAS-mutated melanoma.
Main Methods:
- Identification of STK19 as an NRAS activator through biochemical assays.
- Characterization of STK19 phosphorylation of NRAS and its downstream effects.
- In vivo studies using STK19 D89N knockin models and STK19 inhibitor ZT-12-037-01.
Main Results:
- STK19 was identified as a novel serine/threonine kinase that activates NRAS.
- STK19 enhances NRAS binding to downstream effectors, promoting malignant transformation.
- A gain-of-function STK19 D89N mutation, found in 25% of melanomas, enhances NRAS activity.
- STK19 inhibition by ZT-12-037-01 effectively blocks melanoma growth in vitro and in vivo.
Conclusions:
- STK19 is a key activator of oncogenic NRAS in melanoma.
- STK19 D89N represents a significant oncogenic driver in a subset of melanomas.
- Targeting STK19 with inhibitors like ZT-12-037-01 presents a viable therapeutic strategy for NRAS-mutated melanoma.
Related Concept Videos
00:46Feedback Inhibition
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:30Enzyme Inhibition
01:27ATP Driven Pumps I: An Overview
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
02:34Inhibition of Cdk Activity
01:28Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...